CoChat
Sign Up
Cited by 48

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Exosome-based immunotherapy as an innovative therapeutic approach in melanoma

Babaei, Shabnam, Fadaee, Manouchehr, Abbasi-kenarsari, Hajar, Shanehbandi, Dariush, Kazemi, Tohid·2024·Cell Communication and Signaling
DOI 10.1186/s12964-024-01906-1PMC PMC11526674
Open this paper in CoChat — free account

Abstract

The malignant form of melanoma is one of the deadliest human cancers that accounts for almost all of the skin tumor-related fatalities in its later stages. Achieving an exhaustive understanding of reliable cancer-specific markers and molecular pathways can provide numerous practical techniques and direct the way toward the development of rational curative medicines to increase the lifespan of patients. Immunotherapy has significantly enhanced the treatment of metastatic and late-stage melanoma, resulting in an incredible increase in positive responses to therapy. Despite the increasing occurrence of melanoma, the median survival rate for patients with advanced, inoperable terminal disease has increased from around six months to almost six years. The current knowledge of the tumor microenvironment (TME) and its interaction with the immune system has resulted in the swift growth of innovative immunotherapy treatments. Exosomes are small extracellular vesicles (EVs), ranging from 30 to 150 nm in size, that the majority of cells released them. Exosomes possess natural advantages such as high compatibility with living organisms and low potential for causing immune reactions, making them practical for delivering therapeutic agents like chemotherapy drugs, nucleic acids, and proteins. This review highlights recent advancements in using exosomes as an approach to providing medications for the treatment of melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12964-024-01906-1

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Current therapy methods in melanoma. (A) Targeted therapy, (B) Immune checkpoint inhibitors, (C) Adoptive cell therapy, (D) Oncolytic virus therapy, (E) Cancer vaccine (created by bio render)
Fig. 1 Current therapy methods in melanoma. (A) Targeted therapy, (B) Immune checkpoint inhibitors, (C) Adoptive cell therapy, (D) Oncolytic virus therapy, (E) Cancer vaccine (created by bio render)CC BY · PubMed Central
Fig. 2 Exosome-based immunotherapy in melanoma. Exosome-based therapy in melanoma mainly employs three general methods. (1) Genetic engineering initiates the alterations, allowing the targeted gene to infiltrate the cell via a plasmid, multiply within it, and subsequently release it from the cell via exosomes. (2) Exosome surface modifications involve the use of linkers to introduce materials like antibodies and adhesive molecules onto the exosome’s surface, enabling the exosome to adhere specifically to the target cell. (3) The process involves importing cargo, such as chemotherapy drugs and antigens, and delivering them to the desired cell using mechanical and chemical methods. Modified exosomes can enter the tumor microenvironment and affect various immune cells. For example, in the presence of adjuvants, they can switch macrophages to M1, increase antibody efficacy and T-cell stimulation, enhance dendritic cell maturation, and ultimately increase the immune system’s response to a tumor.
Fig. 2 Exosome-based immunotherapy in melanoma. Exosome-based therapy in melanoma mainly employs three general methods. (1) Genetic engineering initiates the alterations, allowing the targeted gene to infiltrate the cell via a plasmid, multiply within it, and subsequently release it from the cell via exosomes. (2) Exosome surface modifications involve the use of linkers to introduce materials like antibodies and adhesive molecules onto the exosome’s surface, enabling the exosome to adhere specifically to the target cell. (3) The process involves importing cargo, such as chemotherapy drugs and antigens, and delivering them to the desired cell using mechanical and chemical methods. Modified exosomes can enter the tumor microenvironment and affect various immune cells. For example, in the presence of adjuvants, they can switch macrophages to M1, increase antibody efficacy and T-cell stimulation, enhance dendritic cell maturation, and ultimately increase the immune system’s response to a tumor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 185

  1. Mkhobongo B, Chandran R, Abrahamse H. The role of melanoma cell-derived exosomes (MTEX) and photodynamic therapy (PDT) within a tumor microenvironment. Int J Mol Sci. 2021;22(18):9726. · DOI
  2. Surman M, Stępień E, Przybyło M. Melanoma-derived extracellular vesicles: focus on their proteome. Proteomes. 2019;7(2):21. · DOI
  3. Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatology. 2022;158(5):495–503. · DOI
  4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49. · DOI · Paper page
  5. Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Pérez-Fidalgo JA, et al. Melanoma of unknown primary: new perspectives for an old story. Crit Rev Oncol/Hematol. 2021;158:103208. · DOI
  6. Zbytek B, Carlson JA, Granese J, Ross J, Mihm M, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatology. 2008;3(5):569–85. · DOI
  7. Nguyen K, Hignett E, Khachemoune A. Current and emerging treatment options for metastatic melanoma: a focused review. Dermatol Online J. 2020;26(7). · DOI
  8. He G, Li Y, Zeng Y, Zhang Y, Jiang Q, Zhang Q, et al. Advancements in melanoma immunotherapy: the emergence of Extracellular Vesicle vaccines. Cell Death Discovery. 2024;10(1):374. · DOI
  9. Korn EL, Liu P-Y, Lee SJ, Chapman J-AW, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527–34. · DOI
  10. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24(29):4738–45. · DOI
  11. Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatology. 2021;141(1):23–31. · DOI
  12. Xu Z, Zeng S, Gong Z, Yan Y. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer. 2020;19:1–16. · DOI · Paper page
  13. Mason R, Au L, Ingles Garces A, Larkin J. Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opin Pharmacother. 2019;20(9):1135–52. · DOI
  14. Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: recent advances and future directions. Cancers. 2023;15(4):1106. · DOI
  15. Lang B, Peveling-Oberhag A, Faidt D, Hötker A, Weyer-Elberich V, Grabbe S, et al. Long-term survival with modern therapeutic agents against metastatic melanoma—vemurafenib and ipilimumab in a daily life setting. Med Oncol. 2018;35:1–12. · DOI
  16. Drysdale E, Peng Y, Nguyen P, Baetz T, Hanna TP. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma. Melanoma Res. 2019;29(6):635–42. · DOI
  17. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580–7. · DOI
  18. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767–78. · DOI
  19. Robert C, Ribas A, Schachter J, Arance A, Grob J-J, Mortier L, et al. Pembrolizumab versus Ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51. · DOI · Paper page
  20. Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38(33):3937. · DOI
  21. Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med. 2016;14(1):20. · DOI
  22. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8. · DOI
  23. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:1–14. · DOI · Paper page
  24. Maruhashi T, Sugiura D, Okazaki I-m, Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8(2). · DOI
  25. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. · DOI
  26. Renato Filho S, Oliveira DA, Nisimoto MM, Marti LC. A review for Advanced Cutaneous Melanoma therapies and their mechanisms, from immunotherapies to Lysine Histone Methyl Transferase inhibitors. 2023. · DOI
  27. Lopes J, Rodrigues CM, Gaspar MM, Reis CP. Melanoma Management: from epidemiology to treatment and latest advances. Cancers. 2022;14(19):4652. · DOI
  28. Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p. V600E BRAFmutations. BMC Cancer. 2014;14(1):1–13. · DOI
  29. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14. · DOI
  30. Ernst M, Giubellino A. The current state of treatment and future directions in cutaneous malignant melanoma. Biomedicines. 2022;10(4):822. · DOI
  31. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51. · DOI
  32. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus Binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15. · DOI
  33. Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, et al. Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. Eur J Cancer. 2020;126:33–44. · DOI
  34. Li C, Kuai L, Cui R, Miao X. Melanogenesis and the targeted therapy of Melanoma. Biomolecules. 2022;12(12):1874. · DOI
  35. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15(9):954–65. · DOI
  36. Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. OncoTargets Therapy. 2018:7095–107. · DOI · Paper page
  37. Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, et al. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma. Front Immunol. 2019;10:453. · DOI
  38. Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835–44. · DOI · Paper page
  39. Rodríguez-Cerdeira C, Carnero Gregorio M, López-Barcenas A, Sánchez-Blanco E, Sánchez-Blanco B, Fabbrocini G et al. Advances in immunotherapy for melanoma: a comprehensive review. Mediators of inflammation. 2017;2017. · DOI
  40. Payandeh Z, Yarahmadi M, Nariman-Saleh‐Fam Z, Tarhriz V, Islami M, Aghdam AM, et al. Immune therapy of melanoma: overview of therapeutic vaccines. J Cell Physiol. 2019;234(9):14612–21. · DOI
  41. Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Experimental Hematol Oncol. 2022;11(1):1–22. · DOI
  42. Gargett T, Abbas MN, Rolan P, Price JD, Gosling KM, Ferrante A, et al. Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. Cancer Immunol Immunother. 2018;67:1461–72. · DOI
  43. Bulgarelli J, Tazzari M, Granato AM, Ridolfi L, Maiocchi S, De Rosa F et al. Dendritic cell vaccination in metastatic melanoma turns non-T cell inflamed into T-cell inflamed tumors. Front Immunol. 2019:2353. · DOI
  44. Verma V, Kim Y, Lee M-C, Lee J-T, Cho S, Park I-K, et al. Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression. Oncotarget. 2016;7(26):39894. · DOI
  45. Patel SP, Petroni GR, Roszik J, Olson WC, Wages NA, Chianese-Bullock KA et al. Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma. J Immunother Cancer. 2021;9(8). · DOI
  46. Yuan J, Ku GY, Adamow M, Mu Z, Tandon S, Hannaman D, et al. Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. J Immunother Cancer. 2013;1:1–11. · DOI
  47. Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, et al. mRNA-based cancer vaccines: a therapeutic strategy for the treatment of melanoma patients. Vaccines. 2021;9(10):1060. · DOI
  48. Lee S, Margolin K. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep. 2012;14:468–74. · DOI
  49. Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656. · DOI
  50. Haanen J, Rohaan M, Borch T, Van den Berg J, Met Ö, Foppen MG, et al. LBA3 treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: results from a multicenter, randomized phase III trial. Ann Oncol. 2022;33:S1406. · DOI
  51. Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, et al. Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. Front Oncol. 2018;8:44. · DOI
  52. Geukes Foppen MH, Donia M, Borch TH, Met Ö, Blank CU, Pronk L, et al. Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma. American Society of Clinical Oncology; 2016. · DOI
  53. Balch CM, Gershenwald JE, Soong S-j, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199. · DOI
  54. Tarhini AA. The current state of adjuvant therapy of melanoma. Lancet Oncol. 2020;21(11):1394–5. · DOI
  55. Testori AA, Chiellino S, van Akkooi AC. Adjuvant therapy for melanoma: past, current, and future developments. Cancers. 2020;12(7):1994. · DOI
  56. Mocellin S, Lens MB, Pasquali S, Pilati P, Sileni VC. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Reviews. 2013(6). · DOI
  57. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493–501. · DOI
  58. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5):1670–7. · DOI
  59. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–58. · DOI
  60. Eggermont A, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810–8. · DOI
  61. Larkin J, Del Vecchio M, Mandalá M, Gogas H, Arance Fernandez AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023;29(17):3352–61. · DOI
  62. Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643–54. · DOI
  63. Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, et al. Adjuvant pembrolizumab versus IFNα2b or ipilimumab in resected high-risk melanoma. Cancer Discov. 2022;12(3):644–53. · DOI
  64. Qin Z, Zheng M. Advances in targeted therapy and immunotherapy for melanoma. Experimental Therapeutic Med. 2023;26(3):1–23. · DOI
  65. Russell SJ, Peng K-W. Viruses as anticancer drugs. Trends Pharmacol Sci. 2007;28(7):326–33. · DOI
  66. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658. · DOI
  67. Nahand JS, Vandchali NR, Darabi H, Doroudian M, Banafshe HR, Moghoofei M, et al. Exosomal microRNAs: novel players in cervical cancer. Epigenomics. 2020;12(18):1651–60. · DOI
  68. Xiong M, Zhang Q, Hu W, Zhao C, Lv W, Yi Y, et al. The novel mechanisms and applications of exosomes in dermatology and cutaneous medical aesthetics. Pharmacol Res. 2021;166:105490. · DOI
  69. Rahimian S, Najafi H, Afzali B, Doroudian M. Extracellular vesicles and exosomes: novel insights and perspectives on lung cancer from early detection to targeted treatment. Biomedicines. 2024;12(1):123. · DOI
  70. Czystowska-Kuzmicz M, Whiteside TL. The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer. Expert Opin Biol Ther. 2021;21(2):241–58. · DOI
  71. Azhdari MH, Goodarzi N, Doroudian M, MacLoughlin R. Molecular insight into the therapeutic effects of stem cell-derived exosomes in respiratory diseases and the potential for pulmonary delivery. Int J Mol Sci. 2022;23(11):6273. · DOI
  72. Arasi MB, Pedini F, Valentini S, Felli N, Felicetti F. Advances in natural or synthetic nanoparticles for metastatic melanoma therapy and diagnosis. Cancers. 2020;12(10):2893. · DOI
  73. Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56. · DOI · Paper page
  74. Lyu C, Sun H, Sun Z, Liu Y, Wang Q. Roles of exosomes in immunotherapy for solid cancers. Cell Death Dis. 2024;15(2):106. · DOI
  75. Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discovery. 2022;21(7):529–40. · DOI
  76. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94. · DOI · Paper page
  77. Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–8. · DOI
  78. Kalluri R. The biology and function of exosomes in cancer. J Clin Investig. 2016;126(4):1208–15. · DOI
  79. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med. 2013;91:431–7. · DOI
  80. Choi S-J, Cho H, Yea K, Baek M-C. Immune cell-derived small extracellular vesicles in cancer treatment. BMB Rep. 2022;55(1):48. · DOI
  81. Sen S, Xavier J, Kumar N, Ahmad MZ, Ranjan OP. Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. 3 Biotech. 2023;13(3):101. · DOI
  82. Kim H, Jang H, Cho H, Choi J, Hwang KY, Choi Y, et al. Recent advances in exosome-based drug delivery for cancer therapy. Cancers. 2021;13(17):4435. · DOI · Paper page
  83. Ghasempour E, Hesami S, Movahed E, Keshel SH, Doroudian M. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors. Stem Cell Res Ther. 2022;13(1):527. · DOI
  84. Heydari R, Koohi F, Rasouli M, Rezaei K, Abbasgholinejad E, Bekeschus S, et al. Exosomes as rheumatoid arthritis diagnostic biomarkers and therapeutic agents. Vaccines. 2023;11(3):687. · DOI
  85. Moosavian SA, Hashemi M, Etemad L, Daneshmand S, Salmasi Z. Melanoma-derived exosomes: versatile extracellular vesicles for diagnosis, metastasis, immune modulation, and treatment of melanoma. Int Immunopharmacol. 2022;113:109320. · DOI
  86. Syn NL, Wang L, Chow EK-H, Lim CT, Goh B-C. Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges. Trends Biotechnol. 2017;35(7):665–76. · DOI
  87. Akuma P, Okagu OD, Udenigwe CC. Naturally occurring exosome vesicles as potential delivery vehicle for bioactive compounds. Front Sustainable Food Syst. 2019;3:23. · DOI
  88. Yang P, Peng Y, Feng Y, Xu Z, Feng P, Cao J, et al. Immune cell-derived extracellular vesicles–new strategies in cancer immunotherapy. Front Immunol. 2021;12:771551. · DOI
  89. Enomoto Y, Li P, Jenkins LM, Anastasakis D, Lyons GC, Hafner M, et al. Cytokine-enhanced cytolytic activity of exosomes from NK cells. Cancer Gene Ther. 2022;29(6):734–49. · DOI
  90. Cho H, Jung I, Ju H, Baek M-C, Yea K. Engineered CD8 + T cell-derived extracellular vesicles induce enhanced anti-cancer efficacy and targeting to lung cancer cells. Cytokine. 2023;169:156249. · DOI
  91. Jung I, Shin S, Baek M-C, Yea K. Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications. Exp Mol Med. 2024;56(1):19–31. · DOI
  92. Liu C, Liu X, Xiang X, Pang X, Chen S, Zhang Y, et al. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat Nanotechnol. 2022;17(5):531–40. · DOI
  93. Zhou Q, Yan Y, Li Y, Fu H, Lu D, Li Z, et al. Tumor-derived extracellular vesicles in melanoma immune response and immunotherapy. Biomed Pharmacother. 2022;156:113790. · DOI
  94. Hanjani NA, Esmaelizad N, Zanganeh S, Gharavi AT, Heidarizadeh P, Radfar M, et al. Emerging role of exosomes as biomarkers in cancer treatment and diagnosis. Crit Rev Oncol/Hematol. 2022;169:103565. · DOI
  95. Zhang H, Wang S, Sun M, Cui Y, Xing J, Teng L, et al. Exosomes as smart drug delivery vehicles for cancer immunotherapy. Front Immunol. 2023;13:1093607. · DOI
  96. Didiot M-C, Hall LM, Coles AH, Haraszti RA, Godinho BM, Chase K, et al. Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing. Mol Ther. 2016;24(10):1836–47. · DOI · Paper page
  97. Wang D, Wan Z, Yang Q, Chen J, Liu Y, Lu F, et al. Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes. Drug Delivery. 2022;29(1):702–13. · DOI
  98. Xi X-M, Xia S-J, Lu R. Drug loading techniques for exosome-based drug delivery systems. Die Pharmazie-An Int J Pharm Sci. 2021;76(2–3):61–7.
  99. Familtseva A, Jeremic N, Tyagi SC, Exosomes. Cell-created drug delivery systems. Mol Cell Biochem. 2019;459:1–6. · DOI
  100. Pomatto MAC, Bussolati B, D’Antico S, Ghiotto S, Tetta C, Brizzi MF, et al. Improved loading of plasma-derived extracellular vesicles to encapsulate antitumor miRNAs. Mol Therapy-Methods Clin Dev. 2019;13:133–44. · DOI · Paper page
  101. Liao W, Du Y, Zhang C, Pan F, Yao Y, Zhang T, et al. Exosomes: the next generation of endogenous nanomaterials for advanced drug delivery and therapy. Acta Biomater. 2019;86:1–14. · DOI
  102. Salarpour S, Forootanfar H, Pournamdari M, Ahmadi-Zeidabadi M, Esmaeeli M, Pardakhty A. Paclitaxel incorporated exosomes derived from glioblastoma cells: comparative study of two loading techniques. DARU J Pharm Sci. 2019;27:533–9. · DOI
  103. Yang Z, Xie J, Zhu J, Kang C, Chiang C, Wang X, et al. Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation. J Controlled Release. 2016;243:160–71. · DOI
  104. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26(35):5748. · DOI
  105. Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schiffelers RM, Andaloussi SE et al. Extracellular vesicles as drug delivery systems: why and how? Advanced drug delivery reviews. 2020;159:332–43. · DOI
  106. Patras L, Ionescu AE, Munteanu C, Hajdu R, Kosa A, Porfire A, et al. Trojan horse treatment based on PEG-coated extracellular vesicles to deliver doxorubicin to melanoma in vitro and in vivo. Cancer Biol Ther. 2022;23(1):1–16. · DOI
  107. Zhao Y, Gu Y, Qi F, Li A, Tang X, Li D, et al. Engineering adipocytes for targeting delivery of triptolide derivative and Ce6 for malignant melanoma cytotoxic-PDT synergistic strategy. Mater Design. 2023;228:111860. · DOI
  108. Jiang L, Gu Y, Du Y, Tang X, Wu X, Liu J. Engineering exosomes endowed with targeted delivery of triptolide for malignant melanoma therapy. ACS Appl Mater Interfaces. 2021;13(36):42411–28. · DOI
  109. Wang N, Liu C, Li Y, Huang D, Wu X, Kou X, et al. A cooperative nano-CRISPR scaffold potentiates immunotherapy via activation of tumour-intrinsic pyroptosis. Nat Commun. 2023;14(1):779. · DOI
  110. Wang X, Liu Y, Xue C, Hu Y, Zhao Y, Cai K, et al. A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses. Nat Commun. 2022;13(1):5685. · DOI
  111. Li P, Xie Y, Wang J, Bao C, Duan J, Liu Y, et al. Gene engineered exosome reverses T cell exhaustion in cancer immunotherapy. Bioactive Mater. 2024;34:466–81. · DOI
  112. Chen Y-F, Luh F, Ho Y-S, Yen Y. Exosomes: a review of biologic function, diagnostic and targeted therapy applications, and clinical trials. J Biomed Sci. 2024;31(1):67. · DOI
  113. Grolmusz VK, Karászi K, Micsik T, Tóth EA, Mészáros K, Karvaly G, et al. Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. Am J cancer Res. 2016;6(9):2041.
  114. Zheng Z, Li Z, Xu C, Guo B, Guo P. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J Controlled Release. 2019;311:43–9. · DOI
  115. Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, et al. Cancer vaccines: the next immunotherapy frontier. Nat cancer. 2022;3(8):911–26. · DOI
  116. Saxena M, van der Burg SH, Melief CJ, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360–78. · DOI · Paper page
  117. Luo S, Chen J, Xu F, Chen H, Li Y, Li W. Dendritic cell-derived exosomes in cancer immunotherapy. Pharmaceutics. 2023;15(8):2070. · DOI
  118. Xie J, Zheng Z, Tuo L, Deng X, Tang H, Peng C, et al. Recent advances in exosome-based immunotherapy applied to cancer. Front Immunol. 2023;14:1296857. · DOI · Paper page
  119. Hao S, Liu Y, Yuan J, Zhang X, He T, Wu X, et al. Novel exosome-targeted CD4 + T cell vaccine counteracting CD4 + 25 + regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8 + CTL responses. J Immunol. 2007;179(5):2731–40. · DOI
  120. Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298–312. · DOI
  121. Escudier B, Dorval T, Chaput N, André F, Caby M-P, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Translational Med. 2005;3:1–13. · DOI
  122. Damo M, Wilson DS, Simeoni E, Hubbell JA. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. Sci Rep. 2015;5(1):17622. · DOI
  123. Gehrmann U, Hiltbrunner S, Georgoudaki A-M, Karlsson MC, Näslund TI, Gabrielsson S. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. Cancer Res. 2013;73(13):3865–76. · DOI
  124. Kibria G, Ramos EK, Wan Y, Gius DR, Liu H. Exosomes as a drug delivery system in cancer therapy: potential and challenges. Mol Pharm. 2018;15(9):3625–33. · DOI
  125. Naseri M, Bozorgmehr M, Zöller M, Ranaei Pirmardan E, Madjd Z. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy. Oncoimmunology. 2020;9(1):1779991. · DOI
  126. Dai Z, Cai R, Zeng H, Zhu H, Dou Y, Sun S. Exosome may be the next generation of promising cell-free vaccines. Hum Vaccines Immunotherapeutics. 2024;20(1):2345940. · DOI
  127. Li Q, Cai S, Li M, Salma KI, Zhou X, Han F et al. Tumor-derived extracellular vesicles: their role in immune cells and immunotherapy. Int J Nanomed. 2021:5395–409. · DOI
  128. Wang L, Sun Z, Wang H. Extracellular vesicles and the regulation of tumor immunity: current progress and future directions. J Cell Biochem. 2021;122(7):760–9. · DOI
  129. Lee E-Y, Park K-S, Yoon YJ, Lee J, Moon H-G, Jang SC, et al. Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis. PLoS ONE. 2012;7(3):e33330. · DOI
  130. Park KS, Svennerholm K, Crescitelli R, Lässer C, Gribonika I, Lötvall J. Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy. J Extracell Vesicles. 2021;10(9):e12120. · DOI
  131. Lv F, Liu H, Zhao G, Zhao E, Yan H, Che R et al. Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment. Iscience. 2022;25(1). · DOI
  132. Shin S, Jung I, Jung D, Kim CS, Kang S-M, Ryu S, et al. Novel antitumor therapeutic strategy using CD4 + T cell-derived extracellular vesicles. Biomaterials. 2022;289:121765. · DOI
  133. Lu J, Wu J, Xie F, Tian J, Tang X, Guo H, et al. CD4 + T cell-released extracellular vesicles potentiate the efficacy of the HBsAg vaccine by enhancing B cell responses. Adv Sci. 2019;6(23):1802219. · DOI
  134. Wu S-W, Li L, Wang Y, Xiao Z. CTL-derived exosomes enhance the activation of CTLs stimulated by low-affinity peptides. Front Immunol. 2019;10:1274. · DOI
  135. Jung D, Shin S, Kang SM, Jung I, Ryu S, Noh S, et al. Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti‐cancer effects through miRNA delivery. J Extracell Vesicles. 2022;11(12):12287. · DOI
  136. Balsamo M, Pietra G, Vermi W, Moretta L, Mingari MC, Vitale M. Melanoma immunoediting by NK cells. Oncoimmunology. 2012;1(9):1607–9. · DOI
  137. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell functions. Cancer Res. 2012;72(20):5428–9. · DOI
  138. Kang YT, Niu Z, Hadlock T, Purcell E, Lo TW, Zeinali M, et al. On-chip biogenesis of circulating NK cell‐derived exosomes in non‐small cell lung cancer exhibits antitumoral activity. Adv Sci. 2021;8(6):2003747. · DOI
  139. Jong AY, Wu C-H, Li J, Sun J, Fabbri M, Wayne AS, et al. Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles. 2017;6(1):1294368. · DOI
  140. Zhu L, Kalimuthu S, Gangadaran P, Oh JM, Lee HW, Baek SH, et al. Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics. 2017;7(10):2732. · DOI
  141. Fais S. NK cell-released exosomes: natural nanobullets against tumors. Oncoimmunology. 2013;2(1):e22337. · DOI
  142. Lugini L, Cecchetti S, Huber V, Luciani F, Macchia G, Spadaro F, et al. Immune surveillance properties of human NK cell-derived exosomes. J Immunol. 2012;189(6):2833–42. · DOI
  143. Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci. 2008;105(45):17481–6. · DOI
  144. Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol. 2013;4:490. · DOI
  145. Ames E, Hallett W, Murphy W. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Experimental Immunol. 2009;155(3):504–13. · DOI
  146. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284(49):34211–22. · DOI
  147. Meng W, Hao Y, He C, Li L, Zhu G. Exosome-orchestrated hypoxic tumor microenvironment. Mol Cancer. 2019;18:1–14. · DOI
  148. Gharavi AT, Hanjani NA, Movahed E, Doroudian M. The role of macrophage subtypes and exosomes in immunomodulation. Cell Mol Biol Lett. 2022;27(1):83. · DOI
  149. Choo YW, Kang M, Kim HY, Han J, Kang S, Lee J-R, et al. M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors. ACS Nano. 2018;12(9):8977–93. · DOI
  150. Gunassekaran GR, Vadevoo SMP, Baek M-C, Lee B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021;278:121137. · DOI
  151. Wang S, Li F, Ye T, Wang J, Lyu C, Qing S, et al. Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. Sci Transl Med. 2021;13(615):eabb6981. · DOI · Paper page
  152. Padda J, Khalid K, Khedr A, Patel V, Al-Ewaidat OA, Tasnim F, et al. Exosome-derived microRNA: efficacy in cancer. Cureus. 2021;13:8.
  153. Li J, Chen J, Wang S, Li P, Zheng C, Zhou X, et al. Blockage of transferred exosome-shuttled miR‐494 inhibits melanoma growth and metastasis. J Cell Physiol. 2019;234(9):15763–74. · DOI
  154. Ye J, Li D, Jie Y, Luo H, Zhang W, Qiu C. Exosome-based nanoparticles and cancer immunotherapy. Biomed Pharmacother. 2024;179:117296. · DOI
  155. Ye H, Wang K, Zhao J, Lu Q, Wang M, Sun B, et al. In situ sprayed nanovaccine suppressing exosomal PD-L1 by golgi apparatus disorganization for postsurgical melanoma immunotherapy. ACS Nano. 2023;17(11):10637–50. · DOI
  156. Wang G, Xie L, Li B, Sang W, Yan J, Li J, et al. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis. Nat Commun. 2021;12(1):5733. · DOI
  157. Yang Q, Li S, Ou H, Zhang Y, Zhu G, Li S, et al. Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application. J Nanobiotechnol. 2024;22(1):41. · DOI
  158. Wang J, Chen D, Ho EA. Challenges in the development and establishment of exosome-based drug delivery systems. J Controlled Release. 2021;329:894–906. · DOI
  159. Ahn S-H, Ryu S-W, Choi H, You S, Park J, Choi C. Manufacturing therapeutic exosomes: from bench to industry. Mol Cells. 2022;45(5):284–90. · DOI
  160. Tacheny A. Scaling-up the production of stem cell-derived extracellular vesicles in stirred-tank bioreactors. Cell and Gene Therapy Insights; 2021. · DOI
  161. Yamashita T, Takahashi Y, Takakura Y. Possibility of exosome-based therapeutics and challenges in production of exosomes eligible for therapeutic application. Biol Pharm Bull. 2018;41(6):835–42. · DOI
  162. Kong L, Yang C, Zhang Z. Organism-generated Biological vesicles in situ: an Emerging Drug Delivery Strategy. Adv Sci. 2023;10(2):2204178. · DOI
  163. Sanghani A, Andriesei P, Kafetzis KN, Tagalakis AD, Yu-Wai‐Man C. Advances in exosome therapies in ophthalmology–from bench to clinical trial. Acta Ophthalmol. 2022;100(3):243–52. · DOI
  164. Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35(4):851–8. · DOI · Paper page
  165. Chen L-Y, Kao T-W, Chen C-C, Niaz N, Lee H-L, Chen Y-H, et al. Frontier review of the molecular mechanisms and current approaches of stem cell-derived exosomes. Cells. 2023;12(7):1018. · DOI
  166. Negrea G, Rauca V-F, Meszaros MS, Patras L, Luput L, Licarete E, et al. Active tumor-targeting nano-formulations containing simvastatin and doxorubicin inhibit melanoma growth and angiogenesis. Front Pharmacol. 2022;13:870347. · DOI
  167. Kang C, Han P, Lee JS, Lee D, Kim D. Anchor, spacer, and ligand-modified engineered exosomes for trackable targeted therapy. Bioconjug Chem. 2020;31(11):2541–52. · DOI
  168. Gu Y, Du Y, Jiang L, Tang X, Li A, Zhao Y, et al. αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma. J Nanobiotechnol. 2022;20(1):384. · DOI · Paper page
  169. Iessi E, Logozzi M, Lugini L, Azzarito T, Federici C, Spugnini EP, et al. Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: a new prototype for theranostics of tumors. J Enzyme Inhib Med Chem. 2017;32(1):648–57. · DOI
  170. Chen H, Jiang Y, Li X. Adriamycin-loaded exosome with anti‐CD20 aptamers selectively suppresses human CD20 + melanoma stem cells. Skin Res Technol. 2023;29(1):e13259. · DOI
  171. Fan Y, Zhou Y, Lu M, Si H, Li L, Tang B. Responsive dual-targeting exosome as a drug carrier for combination cancer immunotherapy. Research. 2021. · DOI
  172. Lin J, Huang N, Li M, Zheng M, Wang Z, Zhang X, et al. Dendritic cell-derived exosomes driven drug co-delivery biomimetic nanosystem for effective combination of malignant melanoma immunotherapy and gene therapy. Development and Therapy: Drug Design; 2023. pp. 2087–106.
  173. Zhu H, Zhang P, Shi J, Kou D, Bai X. Exosome-delivered circRPS5 inhibits the progression of melanoma via regulating the miR-151a/NPTX1 axis. PLoS ONE. 2023;18(6):e0287347. · DOI
  174. Li J, Li J, Peng Y, Du Y, Yang Z, Qi X. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. J Controlled Release. 2023;353:423–33. · DOI · Paper page
  175. Jung M, Kang M, Kim BS, Hong J, Kim C, Koh CH, et al. Nanovesicle-mediated targeted delivery of immune checkpoint blockades to potentiate therapeutic efficacy and prevent side effects. Adv Mater. 2022;34(9):2106516. · DOI
  176. Fan M, Liu H, Yan H, Che R, Jin Y, Yang X, et al. A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy. Biomaterials. 2022;282:121424. · DOI
  177. Lee YS, Kim SH, Cho JA, Kim CW. Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects. Exp Mol Med. 2011;43(5):281–90. · DOI
  178. Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y. Exosome-based tumor antigens–adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials. 2016;111:55–65. · DOI
  179. Koyama Y, Ito T, Hasegawa A, Eriguchi M, Inaba T, Ushigusa T, et al. Exosomes derived from tumor cells genetically modified to express Mycobacterium tuberculosis antigen: a novel vaccine for cancer therapy. Biotechnol Lett. 2016;38:1857–66. · DOI
  180. Cho J-a, Lee Y-S, Kim S-H, Ko J-K, Kim C-W. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. Cancer Lett. 2009;275(2):256–65. · DOI
  181. Temchura VV, Tenbusch M, Nchinda G, Nabi G, Tippler B, Zelenyuk M, et al. Enhancement of immunostimulatory properties of exosomal vaccines by incorporation of fusion-competent G protein of vesicular stomatitis virus. Vaccine. 2008;26(29–30):3662–72. · DOI
  182. Hu S, Ma J, Su C, Chen Y, Shu Y, Qi Z, et al. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater. 2021;135:567–81. · DOI
  183. Naeem P, Baumgartner A, Ghaderi N, Sefat F, Alhawamdeh M, Heidari S, et al. Anticarcinogenic impact of extracellular vesicles (exosomes) from cord blood stem cells in malignant melanoma: a potential biological treatment. J Cell Mol Med. 2023;27(2):222–31. · DOI
  184. Bae I-S, Kim SH. Milk exosome-derived MicroRNA-2478 suppresses melanogenesis through the akt-gsk3β pathway. Cells. 2021;10(11):2848. · DOI
  185. Shamili FH, Bayegi HR, Salmasi Z, Sadri K, Mahmoudi M, Kalantari M, et al. Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model. Int J Pharm. 2018;549(1–2):218–29. · DOI

Cited by

Sorted by citations

See all 48

Metadata

Authors
Babaei, S., Fadaee, M., Abbasi-kenarsari, H., Shanehbandi, D., & Kazemi, T.
Venue
Cell Communication and Signaling
Publisher
Springer Science and Business Media LLC
Published
2024-10-31
Volume
22
Issue
1
ISSN
1478-811X
DOI
10.1186/s12964-024-01906-1
PMC
PMC11526674
Cited by
48
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exosome-based immunotherapy as an innovative therapeutic approach in melanoma. https://app.cochat.ai/papers/10.1186/s12964-024-01906-1
The paper
Babaei, S., Fadaee, M., Abbasi-kenarsari, H., Shanehbandi, D., & Kazemi, T. (2024). Exosome-based immunotherapy as an innovative therapeutic approach in melanoma. Cell Communication and Signaling. https://doi.org/10.1186/s12964-024-01906-1